TNSN97135A1 - Derives 6,6- ou 6,7 bicycliques a noyau pyrido ou pyrimido substitues - Google Patents
Derives 6,6- ou 6,7 bicycliques a noyau pyrido ou pyrimido substituesInfo
- Publication number
- TNSN97135A1 TNSN97135A1 TNTNSN97135A TNSN97135A TNSN97135A1 TN SN97135 A1 TNSN97135 A1 TN SN97135A1 TN TNSN97135 A TNTNSN97135 A TN TNSN97135A TN SN97135 A TNSN97135 A TN SN97135A TN SN97135 A1 TNSN97135 A1 TN SN97135A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pyrimido
- pyrido
- bicyclic derivatives
- cores
- substituted
- Prior art date
Links
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000590 parasiticidal effect Effects 0.000 abstract 1
- 239000002297 parasiticide Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'INVENTION CONCERNE DES PYRAZOLES PARASITICIDES NOUVEAUX DE FORMULE I .............................DANS LAQUELLE A, B, D, E, K, G, Z, R3 ET R5 REPRESENTENT DIVERS ATOMES OU RADICAUX . ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUEMENT LES CONTENANT. APPLICATION: UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES QUI PEUT ETRE EFFECTUE OU FACILITE PAR ANTAGONISATION DU FACTEUR DE LIBERATION DE CORTICOTROPHINE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2345396P | 1996-08-06 | 1996-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN97135A1 true TNSN97135A1 (fr) | 2005-03-15 |
Family
ID=21815208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN97135A TNSN97135A1 (fr) | 1996-08-06 | 1997-08-06 | Derives 6,6- ou 6,7 bicycliques a noyau pyrido ou pyrimido substitues |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6492520B1 (fr) |
| EP (1) | EP0920429B1 (fr) |
| JP (1) | JP3345021B2 (fr) |
| KR (1) | KR20000029843A (fr) |
| CN (1) | CN1093130C (fr) |
| AP (1) | AP1096A (fr) |
| AR (1) | AR008829A1 (fr) |
| AT (1) | ATE232863T1 (fr) |
| AU (1) | AU709203B2 (fr) |
| BG (1) | BG103143A (fr) |
| BR (1) | BR9710808A (fr) |
| CA (1) | CA2262692C (fr) |
| CO (1) | CO4900060A1 (fr) |
| CZ (1) | CZ292806B6 (fr) |
| DE (1) | DE69719193T2 (fr) |
| DK (1) | DK0920429T3 (fr) |
| DZ (1) | DZ2289A1 (fr) |
| EA (1) | EA003188B1 (fr) |
| ES (1) | ES2191183T3 (fr) |
| GT (1) | GT199700089A (fr) |
| HR (1) | HRP970432B1 (fr) |
| ID (1) | ID17980A (fr) |
| IL (1) | IL128188A0 (fr) |
| IS (1) | IS4948A (fr) |
| MA (1) | MA24296A1 (fr) |
| NO (1) | NO313293B1 (fr) |
| NZ (1) | NZ333727A (fr) |
| OA (1) | OA10970A (fr) |
| PA (1) | PA8435201A1 (fr) |
| PE (1) | PE97098A1 (fr) |
| PL (1) | PL331602A1 (fr) |
| SA (1) | SA97180334A (fr) |
| SK (1) | SK14099A3 (fr) |
| TN (1) | TNSN97135A1 (fr) |
| TR (1) | TR199900228T2 (fr) |
| TW (1) | TW550265B (fr) |
| UY (1) | UY24655A1 (fr) |
| WO (1) | WO1998005661A1 (fr) |
| YU (1) | YU5399A (fr) |
| ZA (1) | ZA976954B (fr) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6599910B1 (en) | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
| PT1129091E (pt) | 1998-11-12 | 2003-02-28 | Neurocrine Biosciences Inc | Antagonistas de receptor de crf e metodos relacionados |
| JP2002529469A (ja) | 1998-11-12 | 2002-09-10 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | Ｃｒｆレセプターアンタゴニストおよびそれに関する方法 |
| US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
| CO5271670A1 (es) * | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| AU2001232271A1 (en) * | 2000-02-14 | 2001-08-20 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
| WO2001062718A1 (fr) * | 2000-02-25 | 2001-08-30 | Japan Tobacco, Inc. | Dérivé de benzamide et utilisation de celui-ci |
| AR030053A1 (es) * | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| GB0011964D0 (en) | 2000-05-18 | 2000-07-05 | Suyal N | Thick glass films with controlled refractive indices and their applications |
| EP2404603A1 (fr) | 2000-10-23 | 2012-01-11 | Glaxosmithkline LLC | Nouveaux composés 8H-pyrido[2,3-d]pyrimidin-7-one trisubstituté pour le traitement des maladies faisant intervenir les kinases CSBP/p38. |
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| US6677352B1 (en) | 2001-09-26 | 2004-01-13 | Yamin Wang | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders |
| US7629350B2 (en) * | 2002-04-19 | 2009-12-08 | Smithkline Beecham Corporation | Compounds |
| FR2846657B1 (fr) * | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| OA13309A (en) | 2002-12-20 | 2007-04-13 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| WO2006074147A2 (fr) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Composes et utilisation therapeutique associee |
| WO2005003100A2 (fr) | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | Composes et leur utilisation therapeutique |
| US20050085479A1 (en) * | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| EP1732541A4 (fr) * | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | Composes cycliques |
| WO2005111024A1 (fr) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Derives de pyrimidine destines au traitement de croissance cellulaire anormale |
| JP2007537238A (ja) | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療のためのピリミジン誘導体 |
| WO2005111022A1 (fr) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Derives pyrimidiques pour le traitement de la croissance de cellules anormales |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| PE20100741A1 (es) * | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
| TWI389690B (zh) * | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | 新穎化合物（一） |
| US20080096905A1 (en) | 2005-03-25 | 2008-04-24 | Glaxo Group Limited | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives |
| WO2006110298A2 (fr) | 2005-03-25 | 2006-10-19 | Glaxo Group Limited | Nouveaux composes |
| ES2393768T3 (es) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Derivado de quinolina para el tratamiento de enfermedades retinianas |
| RU2467007C2 (ru) | 2005-12-21 | 2012-11-20 | Эбботт Лэборетриз | Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv |
| ES2378473T3 (es) | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Compuestos antivirales |
| EP2345652A1 (fr) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Composées antivirales |
| EP1971611B1 (fr) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Composes anti-viraux |
| JP2009521460A (ja) * | 2005-12-21 | 2009-06-04 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| EA026557B1 (ru) | 2008-12-09 | 2017-04-28 | Джилид Сайэнс, Инк. | Промежуточные соединения для получения модуляторов толл-подобных рецепторов |
| US8551996B2 (en) * | 2009-02-20 | 2013-10-08 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
| CA2772253C (fr) | 2009-09-14 | 2018-02-27 | Gilead Sciences, Inc. | Modulateurs des recepteurs de type toll (tlr) |
| CA2782015C (fr) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Compositions ophthalmiques topiques et methodes de traitement de la degenerescence maculaire |
| WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| HK1217439A1 (zh) | 2013-01-23 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 与毒性醛相关的疾病和治疗 |
| KR102469849B1 (ko) | 2013-04-19 | 2022-11-23 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| ES2949660T3 (es) * | 2014-05-15 | 2023-10-02 | Hoffmann La Roche | Procedimiento para la preparación de compuestos útiles para tratar la atrofia muscular espinal |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| CN107074860B (zh) | 2014-09-16 | 2022-07-15 | 吉利德科学公司 | 制备toll样受体调节剂的方法 |
| AU2015318061B2 (en) | 2014-09-16 | 2018-05-17 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| HK1255074A1 (zh) | 2015-07-01 | 2019-08-02 | Crinetics Pharmaceuticals, Inc. | 生长抑素调节剂及其用途 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN109069498B (zh) * | 2016-02-12 | 2021-08-17 | 细胞动力学股份有限公司 | 四氢异喹啉衍生物 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019023278A1 (fr) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et utilisations de ces derniers |
| AU2018348174A1 (en) * | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| EP3788046B1 (fr) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Sels d'un inhibiteur de fgfr |
| EP4309737A3 (fr) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
| AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020068986A1 (fr) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations pour le traitement de la maladie de l'œil sec |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| JP7706758B2 (ja) | 2019-03-26 | 2025-07-14 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| CA3137301A1 (fr) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Composes polymorphes et leurs utilisations |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (fr) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr |
| WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3175856A1 (fr) | 2020-05-13 | 2021-11-18 | Todd Brady | Formulations pharmaceutiques et leurs utilisations |
| CA3215903A1 (fr) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Polytherapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4 |
| EP4352059A1 (fr) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
| WO2022261159A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| WO1994013676A1 (fr) * | 1992-12-17 | 1994-06-23 | Pfizer Inc. | Pyrrolopyrimidines en tant qu'antagonistes du facteur liberateur de corticotrophine (crf) |
| TW370529B (en) * | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| ATE182332T1 (de) * | 1994-06-16 | 1999-08-15 | Pfizer | Pyrazolo und pyrrolopyridine |
| JP2898887B2 (ja) * | 1994-08-31 | 1999-06-02 | 沖電気工業株式会社 | Ｉｃカードの読み取り装置 |
| EP0729758A3 (fr) * | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies |
| WO1996035689A1 (fr) * | 1995-05-12 | 1996-11-14 | Neurogen Corporation | Derives nouveaux de deazapurine; une nouvelle classe de ligands specifiques de crf1 |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| DK0778277T3 (da) * | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
| TR199800792T2 (xx) | 1996-02-07 | 1998-07-21 | Janssen Pharmaceutica N.V. | CRF resept�r antagonistleri olarak pirazolopirimidinler. |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
-
1997
- 1997-07-23 EA EA199900083A patent/EA003188B1/ru not_active IP Right Cessation
- 1997-07-23 DE DE69719193T patent/DE69719193T2/de not_active Expired - Fee Related
- 1997-07-23 TR TR1999/00228T patent/TR199900228T2/xx unknown
- 1997-07-23 BR BR9710808A patent/BR9710808A/pt not_active Application Discontinuation
- 1997-07-23 SK SK140-99A patent/SK14099A3/sk unknown
- 1997-07-23 IL IL12818897A patent/IL128188A0/xx unknown
- 1997-07-23 WO PCT/IB1997/000918 patent/WO1998005661A1/fr not_active Ceased
- 1997-07-23 YU YU5399A patent/YU5399A/sh unknown
- 1997-07-23 NZ NZ333727A patent/NZ333727A/xx unknown
- 1997-07-23 CZ CZ1999411A patent/CZ292806B6/cs not_active IP Right Cessation
- 1997-07-23 CN CN97197079A patent/CN1093130C/zh not_active Expired - Fee Related
- 1997-07-23 PL PL97331602A patent/PL331602A1/xx unknown
- 1997-07-23 EP EP97929472A patent/EP0920429B1/fr not_active Expired - Lifetime
- 1997-07-23 ES ES97929472T patent/ES2191183T3/es not_active Expired - Lifetime
- 1997-07-23 KR KR1019997001005A patent/KR20000029843A/ko not_active Abandoned
- 1997-07-23 AU AU33563/97A patent/AU709203B2/en not_active Ceased
- 1997-07-23 JP JP50775498A patent/JP3345021B2/ja not_active Expired - Fee Related
- 1997-07-23 CA CA002262692A patent/CA2262692C/fr not_active Expired - Fee Related
- 1997-07-23 DK DK97929472T patent/DK0920429T3/da active
- 1997-07-23 US US09/242,076 patent/US6492520B1/en not_active Expired - Fee Related
- 1997-07-23 AT AT97929472T patent/ATE232863T1/de not_active IP Right Cessation
- 1997-07-31 AP APAP/P/1997/001052A patent/AP1096A/en active
- 1997-08-04 GT GT199700089A patent/GT199700089A/es unknown
- 1997-08-04 TW TW086111115A patent/TW550265B/zh active
- 1997-08-05 AR ARP970103560A patent/AR008829A1/es not_active Application Discontinuation
- 1997-08-05 PE PE1997000679A patent/PE97098A1/es not_active Application Discontinuation
- 1997-08-05 CO CO97044966A patent/CO4900060A1/es unknown
- 1997-08-05 PA PA19978435201A patent/PA8435201A1/es unknown
- 1997-08-05 ZA ZA976954A patent/ZA976954B/xx unknown
- 1997-08-05 ID IDP972708A patent/ID17980A/id unknown
- 1997-08-05 UY UY24655A patent/UY24655A1/es not_active IP Right Cessation
- 1997-08-06 DZ DZ970139A patent/DZ2289A1/fr active
- 1997-08-06 TN TNTNSN97135A patent/TNSN97135A1/fr unknown
- 1997-08-06 MA MA24755A patent/MA24296A1/fr unknown
- 1997-08-06 HR HR970432A patent/HRP970432B1/xx not_active IP Right Cessation
- 1997-08-25 SA SA97180334A patent/SA97180334A/ar unknown
-
1999
- 1999-01-19 IS IS4948A patent/IS4948A/is unknown
- 1999-02-03 OA OA9900024A patent/OA10970A/en unknown
- 1999-02-03 BG BG103143A patent/BG103143A/xx unknown
- 1999-02-05 NO NO19990544A patent/NO313293B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN97135A1 (fr) | Derives 6,6- ou 6,7 bicycliques a noyau pyrido ou pyrimido substitues | |
| TNSN97144A1 (fr) | Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99236A1 (fr) | Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN01091A1 (fr) | Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale | |
| TNSN99162A1 (fr) | Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99106A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN98238A1 (fr) | Macrolides nouveaux | |
| TNSN97148A1 (fr) | Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99156A1 (fr) | Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN97192A1 (fr) | Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN97108A1 (fr) | Analogues d'indazole nouveaux | |
| TNSN99169A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26718A1 (fr) | Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99142A1 (fr) | Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation. | |
| TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
| TNSN97197A1 (fr) | Derives de pyrazole parasiticides, procede pour leur preparation et compositions les contenant. | |
| TNSN98022A1 (fr) | DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. | |
| TNSN98019A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN00104A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN98194A1 (fr) | Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN00235A1 (fr) | Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant | |
| TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN01134A1 (fr) | Derives de purine nouveaux, procede pour leur preparation et compositions les contenant. | |
| TNSN98035A1 (fr) | Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant | |
| TNSN00108A1 (fr) | Derives d'erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant |